16 October 2024
EMA/484982/2024
EMEA/H/C/003788

Public statement

Ciambra (pemetrexed)

Withdrawal of the marketing authorisation in the European Union

On 12 October.2023, the European Commission withdrew the marketing authorisation for Ciambra (pemetrexed) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Menarini International Operations Luxembourg S.A., which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Ciambra was granted marketing authorisation in the EU on 2 December 2015 for the treatment of malignant pleural mesothelioma and non-small cell lung cancer. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2019. The product had not been marketed in the EU since 2021.

Ciambra is a generic medicine of Alimta. There are other generic medicinal products of Alimta authorised and marketed in the EU.

The European Public Assessment Report (EPAR) for Ciambra will be updated to indicate that the marketing authorisation is no longer valid.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union